Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPERFUSE: Cangrelor in Addition to Mechanical Thrombectomy for Acute Ischemic Stroke
NCT04667078Phase 3Suspended
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cangrelor in ischemic stroke (2 arms), sponsored by Adolphe de Rothschild Foundation Hospital. Primary endpoint: Favorable functional evaluation at 3 months. Started Mar 2022; status: suspended.
02
Drugs
cangrelor
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04667078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667078.